Todd Wood.

ATLANTA—Alimera Sciences, Inc. (Nasdaq: ALIM), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announced the appointment of Todd Wood as president of U.S. operations, effective immediately. “As we prepare to enter 2024 with a significantly larger U.S. business, we are excited to have Todd join our team to oversee our U.S. operations and accelerate our growth trajectory,” said Rick Eiswirth, Alimera’s president and CEO. “Todd brings strong commercial leadership across sales, marketing and market access from both the pharmaceutical and medical device industries, including leading the eyecare sales organization at Allergan.”

Wood spent the majority of his career at Allergan, an AbbVie company, where he held a variety of roles including vice president of U.S. sales, eyecare, area director, facial aesthetics and senior product manager, Lumigan (glaucoma product). He most recently served as chief commercial officer at Dermtech International, a leading genomics company in dermatology. Previously, he was vice president, global sales at Obalon Therapeutics, which focused on developing and commercializing novel technologies for weight loss before merging with ReShape Lifesciences in 2021.

“I’m looking forward to building upon Alimera’s strong foundation to establish a program for long-term success,” said Wood. “I strongly believe that Iluvien and Yutiq provide unique opportunities to better control diabetic macular edema and uveitis, reduce the recurrence of both diseases and help patients see longer with fewer injections, and I look forward to driving increased utilization of both products.”